Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-10
2006-01-10
Zucker, Paul A. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S358000, C514S400000, C514S563000, C514S568000, C546S342000, C546S347000, C548S341500, C562S476000
Reexamination Certificate
active
06984645
ABSTRACT:
Compounds that are dual aP2/k-FABP inhibitors are provided having the formulawherein A, B, X, Y, R1, R2and R3are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing dual aP2/k-FABP inhibitors alone or in combination with at least one other antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.
REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4046889 (1977-09-01), Ondetti et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4316906 (1982-02-01), Ondetti et al.
patent: 4337201 (1982-06-01), Petrillo, Jr.
patent: 4344949 (1982-08-01), Hoefle et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4374829 (1983-02-01), Harris et al.
patent: 4432971 (1984-02-01), Karanewsky et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4452790 (1984-06-01), Karanewsky et al.
patent: 4473575 (1984-09-01), Watthey
patent: 4499289 (1985-02-01), Baran et al.
patent: 4572912 (1986-02-01), Yoshioka et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4639436 (1987-01-01), Junge et al.
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4686237 (1987-08-01), Anderson
patent: 4722810 (1988-02-01), Delaney et al.
patent: 4749688 (1988-06-01), Haslanger et al.
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4904769 (1990-02-01), Rauenbusch
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5223516 (1993-06-01), Delaney et al.
patent: 5225401 (1993-07-01), Seymour
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5346701 (1994-09-01), Heiber et al.
patent: 5354772 (1994-10-01), Kathawala
patent: 5362727 (1994-11-01), Robl
patent: 5366973 (1994-11-01), Flynn et al.
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5447954 (1995-09-01), Gribble et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5504080 (1996-04-01), Karanewsky
patent: 5506219 (1996-04-01), Robl
patent: 5525723 (1996-06-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5552397 (1996-09-01), Karanewsky et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5614492 (1997-03-01), Habener
patent: 5631224 (1997-05-01), Efendic et al.
patent: 5686104 (1997-11-01), Mills et al.
patent: 5691322 (1997-11-01), Robl
patent: 5698527 (1997-12-01), Kim
patent: 5712279 (1998-01-01), Biller et al.
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5760246 (1998-06-01), Biller et al.
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5827875 (1998-10-01), Dickson, Jr. et al.
patent: 5885983 (1999-03-01), Biller et al.
patent: 5962440 (1999-10-01), Sulsky
patent: 6218408 (2001-04-01), Marzabadi et al.
patent: 6395767 (2002-05-01), Robl et al.
patent: 6414002 (2002-07-01), Cheng et al.
patent: 6414126 (2002-07-01), Ellsworth et al.
patent: 19622222 (1997-12-01), None
patent: 060668 (1982-09-01), None
patent: 079022 (1983-05-01), None
patent: 080822 (1983-06-01), None
patent: 142146 (1985-05-01), None
patent: 221025 (1987-05-01), None
patent: 481522 (1992-04-01), None
patent: 534363 (1993-03-01), None
patent: 534396 (1993-03-01), None
patent: 534492 (1993-03-01), None
patent: 595610 (1994-05-01), None
patent: 599444 (1994-06-01), None
patent: 629627 (1994-12-01), None
patent: 675714 (1995-10-01), None
patent: 2596393 (1987-10-01), None
patent: 2103614 (1983-02-01), None
patent: 2304106 (1997-03-01), None
patent: WO 86/03488 (1986-06-01), None
patent: WO 86/07054 (1986-12-01), None
patent: WO 94/15592 (1994-07-01), None
patent: WO 96/38144 (1996-12-01), None
patent: WO 97/12613 (1997-04-01), None
patent: WO 97/12615 (1997-04-01), None
patent: WO 97/21993 (1997-06-01), None
patent: WO 97/35576 (1997-10-01), None
patent: WO 97/48701 (1997-12-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/58518 (1999-11-01), None
patent: WO 99/58522 (1999-11-01), None
patent: WO 99/58552 (1999-11-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/61435 (1999-12-01), None
patent: WO 99/67278 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO 00/15229 (2000-03-01), None
patent: WO 00/50574 (2000-08-01), None
patent: WO 00/59506 (2000-10-01), None
patent: WO 01/13917 (2001-03-01), None
patent: WO 01/14376 (2001-03-01), None
patent: WO 01/44239 (2001-06-01), None
patent: WO 01/60784 (2001-08-01), None
US 4,385,051, 5/1983, Oka et al. (withdrawn)
Ashworth, D.M. et al., “2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinial Chemistry Letters, vol. 6, No. 10, pp. 1163-1166 (1996).
Ashworth, D.M. et al., “4-Cyanothiazolidides as Very Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinial Chemistry Letters, vol. 6, No. 22, pp. 2745-2748 (1996).
Attwood, M.R. et al., “New potent inhibitors of angiotensin converting enzyme”, FEBS, vol. 165, No. 2, pp. 201-206 (1984).
Baum, T. et al., “Antihypertensive Activity of SCH 31846, a Non-Sulfhydryl Angiotensin-Converting Enzyme Inhibitor”, Journal of Cardiovascular Pharmacology, vol. 5, No. 4, pp. 655-667 (1983).
Biller, S.A. et al., “Isoprenoid (Phosphinylmethyl)phosphonates as Inhibitors of Squalene Synthetase”, Journal of Medicinal Chemistry, vol. 31, No. 10, pp. 1869-1871 (1988).
Biller, S.A. et al., “Squalene Synthase Inhibitors”, Current Pharmaceutical Design, vol. 2, pp. 1-40 (1996).
Bristol-Myers Squibb Company newsletter, vol. 7, No. 3, pp. 20-21 (1996).
Capson, T.L., “Synthesis and Evaluation of Ammonium Analogs of Carbocationic Intermediates in Squalene Biosynthesis”, dissertation, Department of Medicinal Chemistry, University of Utah, pp. iv-v, Table of Contents, 16-17, 40-43, 48-51, Summary (Jun. 1987).
Carlsson, A. et al., “In den Catecholamin-Metabolismus eingreifende Substanzen. 3. 2,3-Dihydroxyphenylacetamide und verwandte Verbindungen”, Helvetica Chimica Acta, vol. 47, No. 5, pp. 1340-1349 (1964).
Chemical Abstracts, vol. 102, 72588v, p. 40 (1985).
Cohen, D.M. et al., “CI-925: A New Orally Active Non-sulfhydryl Angiotensin Converting Enzyme (ACE) Inhibitor” (53, 266), The Pharmacologist, FASEB Meeting Information, vol. 26, No. 1, p. 177 (1984).
Corey, E.J. et al., “Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Multistep Biosynthesis. Demonstration That ‘Presqualene Pyrophosphate’ Is an Essential Intermediate on the Path to Squalene”, J. Am. Chem. Soc., vol. 98, No. 5, pp. 1291-1293 (1976).
Cornicelli, J.A. et al., “15-Lipoxygenase and Its Inhibition: A Novel Therapeutic Target for Vascular Disease”, Current Pharmaceutical Design, vol. 5, pp. 11-20 (1999).
Easton, M.L. et al., “Metabolic disposition of CI-925-14C, a potent ACE inhibitor in rats and dogs” (30, 243), The Pharmacologist, FASEB Meeting Information, vol. 26, No. 1, p. 172 (1984).
Ghiselli, G., “The Pharmacological Profile of FCE 27677: A Novel ACAT Inhibitor with Potent Hypolipidemic Activity Mediated by Selective Suppression of the Hepatic Secretion of ApoB-100-Containing Lipoprotein”, Cardiovascular Drug Reviews, vol. 16, No. 1, pp. 16-30 (1998).
Hotamisligil, G.S. et al., “Uncoupling of Obesity from Insulin Resistance Through a Targeted Mutation in aP2, the Adipocyte Fatty Acid Binding Protein”, Science, vol. 274, pp. 1377-1379 (1996).
Hughes, T.E. et al.,
Caulfield Thomas J.
Magnin David R.
Parker Rex A.
Robl Jeffrey A.
Sulsky Richard B.
Bristol--Myers Squibb Company
Duncan Laurelee A.
Wang Joseph C.
Zucker Paul A.
LandOfFree
Dual inhibitors of adipocyte fatty acid binding protein and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dual inhibitors of adipocyte fatty acid binding protein and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dual inhibitors of adipocyte fatty acid binding protein and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3574776